Welcome back to the Pear Healthcare Playbook! Every week, we’ll be getting to know trailblazing healthcare leaders and diving into building a digital health and biotech business from 0 to 1.
We would greatly appreciate it if you took a moment to listen to the episode on either Apple or Spotify and leave us a rating! Your support helps our guests' insights reach a larger audience!
Today we're thrilled to host Anirudh Joshi, co-founder of Valar Labs, who is building the company with co-founder Viswesh Krishna. Valar is pioneering AI-native oncology diagnostics using standard pathology slides to predict treatment response, starting with bladder cancer and expanding across oncology.
The company raised a $22M Series A co-led by DCVC and Andreessen Horowitz, with continued backing from Pear VC since day one. In this conversation, Anirudh walks through how the genesis of the company, why pathology has long been underutilized and what it took to bring Vesta, its genitourinary-focused portfolio of AI powered pathology tests, to the clinic.
Podden och tillhörande omslagsbild på den här sidan tillhör
Pear VC. Innehållet i podden är skapat av Pear VC och inte av,
eller tillsammans med, Poddtoppen.
